Intas Pharmaceuticals (Accord Healthcare)
A privately held Ahmedabad company whose European arm, Accord Healthcare, is one of the largest suppliers of generic chemotherapy and supportive-care biosimilars to European hospitals.
Overview
Intas was founded in 1977 by Hasmukh Chudgar and incorporated in 1985; it operates 22 manufacturing plants and sells in more than 100 countries, with revenue heading toward 24,000 crore rupees. Its Biologics Unit was the first Indian company to receive EU GMP certification (April 2007), and its London-based subsidiary Accord Healthcare markets generics and biosimilars across Europe and North America, including the pegfilgrastim biosimilar Pelgraz (EMA authorisation 21 September 2018) used to prevent chemotherapy-induced neutropenia. Accord's injectable oncology generics are a staple of European hospital pharmacies.
Pages like this
not linked directly; found by shared links- CompanyLupin
Shares Prices and value, Cytotoxic chemotherapy.
- IdeaDrop the extra switching studies for interchangeable oncology biosimilars
Shares Biosimilar, Prices and value.
- IdeaPay a flat fee for giving a Part B drug instead of 6% of its price
Shares Biosimilar, Prices and value.
- IdeaMake the biosimilar the default at the pharmacy for trastuzumab, bevacizumab and rituximab
Shares Biosimilar, Prices and value.
- CompanyHetero Drugs
Shares Biosimilar, Prices and value.
- IdeaA non-profit manufacturer for generic cancer drugs in chronic shortage
Shares Prices and value, Cytotoxic chemotherapy.
- CompanyCipla
Shares Prices and value, Cytotoxic chemotherapy.
- CompanyDr. Reddy's Laboratories
Shares Biosimilar, Prices and value.